据报道，欧盟委员会可能将无条件批准诺和诺德母公司Novo Holdings以165亿美元收购美国合同制药商Catalent的交易。欧盟委员会将在12月6日之前决定是否 ...

Novo Holdings won European Union antitrust approval for its planned $16.5 billion purchase of Catalent (NYSE:CTLT). The deal is expected to close towards the end of calendar year 2024, subject to ...

Dec 14 (Reuters) - All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent (CTLT.N), opens new tab had been fulfilled ...

Update 12:35pm: Adds Reuters report. Catalent (NYSE:CTLT) rose 2.2% amid reports that the European Union's antitrust regulator will likely grant approval for its planned sale to Novo Holdings ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have said they expect to close before year-end—just received a major ...

Novo Holdings, the controlling shareholder of Novo Nordisk , on Wednesday sealed its $16.5 billion deal for Catalent , as the Danish drugmaker looks to boost supplies of its widely popular weight ...

In recent trading, shares of Catalent Inc (Symbol: CTLT) have crossed above the average analyst 12-month target price of $63.42, changing hands for $63.48/share. When a stock reaches the target an ...